112 related articles for article (PubMed ID: 38710487)
1. ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).
Fontana E; Rosen E; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Cote GM; Carter L; Plummer R; Mahalingam D; Fretland AJ; Schonhoft JD; Silverman IM; Wainszelbaum M; Xu Y; Ulanet D; Koehler M; Yap TA
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38710487
[TBL] [Abstract][Full Text] [Related]
2. Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Black WC; Abdoli A; An X; Auger A; Beaulieu P; Bernatchez M; Caron C; Chefson A; Crane S; Diallo M; Dorich S; Fader LD; Ferraro GB; Fournier S; Gao Q; Ginzburg Y; Hamel M; Han Y; Jones P; Lanoix S; Lacbay CM; Leclaire ME; Levy M; Mamane Y; Mulani A; Papp R; Pellerin C; Picard A; Skeldon A; Skorey K; Stocco R; St-Onge M; Truchon JF; Truong VL; Zimmermann M; Zinda M; Roulston A
J Med Chem; 2024 Feb; 67(4):2349-2368. PubMed ID: 38299539
[TBL] [Abstract][Full Text] [Related]
3. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA; Fontana E; Lee EK; Spigel DR; Højgaard M; Lheureux S; Mettu NB; Carneiro BA; Carter L; Plummer R; Cote GM; Meric-Bernstam F; O'Connell J; Schonhoft JD; Wainszelbaum M; Fretland AJ; Manley P; Xu Y; Ulanet D; Rimkunas V; Zinda M; Koehler M; Silverman IM; Reis-Filho JS; Rosen E
Nat Med; 2023 Jun; 29(6):1400-1411. PubMed ID: 37277454
[TBL] [Abstract][Full Text] [Related]
4. Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.
Rosen E; Yap TA; Lee EK; Højgaard M; Mettu NB; Lheureux S; Carneiro BA; Plummer R; Fretland AJ; Ulanet D; Xu Y; McDougall R; Koehler M; Fontana E
Clin Cancer Res; 2024 Feb; 30(4):687-694. PubMed ID: 38078898
[TBL] [Abstract][Full Text] [Related]
5. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C; Chénard-Poirier M; Roda D; de Miguel M; Harris SJ; Candilejo IM; Sriskandarajah P; Xu W; Scaranti M; Constantinidou A; King J; Parmar M; Turner AJ; Carreira S; Riisnaes R; Finneran L; Hall E; Ishikawa Y; Nakai K; Tunariu N; Basu B; Kaiser M; Lopez JS; Minchom A; de Bono JS; Banerji U
Lancet Oncol; 2020 Nov; 21(11):1478-1488. PubMed ID: 33128873
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
[TBL] [Abstract][Full Text] [Related]
7. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Falchook GS; Sachdev J; Imedio ER; Kumar S; Mugundu GM; Jenkins S; Chmielecki J; Jones S; Spigel DR; Johnson M
Invest New Drugs; 2023 Jun; 41(3):493-502. PubMed ID: 37171722
[TBL] [Abstract][Full Text] [Related]
9. Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP; Italiano A; Awada A; Aftimos P; Houédé N; Lebbé C; Pages C; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Faivre S; Gomez-Roca C; Scheuler A; Massimini G; Raymond E
Target Oncol; 2021 Jan; 16(1):37-46. PubMed ID: 33170484
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors.
Richardson GE; Al-Rajabi R; Uprety D; Hamid A; Williamson SK; Baranda J; Mamdani H; Lee YL; Nitika ; Li L; Wang X; Dong X
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174019
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao J; Guo H; Ji D; Shen W; Zhang S; Hsieh CY; Xiong Cai S; Edward Tian Y; Xu C; Zhang P; Xu B
Oncologist; 2023 Dec; 28(12):e1259-e1267. PubMed ID: 37338150
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Gan HK; Millward M; Hua Y; Qi C; Sai Y; Su W; Wang J; Zhang L; Frigault MM; Morgan S; Yang L; Lickliter JD
Clin Cancer Res; 2019 Aug; 25(16):4924-4932. PubMed ID: 30952639
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Moreno V; Sepulveda JM; Vieito M; Hernández-Guerrero T; Doger B; Saavedra O; Ferrero O; Sarmiento R; Arias M; De Alvaro J; Di Martino J; Zuraek M; Sanchez-Pérez T; Aronchik I; Filvaroff EH; Lamba M; Hanna B; Nikolova Z; Braña I
Ann Oncol; 2020 Jun; 31(6):780-788. PubMed ID: 32240793
[TBL] [Abstract][Full Text] [Related]
15. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Aghajanian C; Bell-McGuinn KM; Burris HA; Siu LL; Stayner LA; Wheler JJ; Hong DS; Kurkjian C; Pant S; Santiago-Walker A; Gauvin JL; Antal JM; Opalinska JB; Morris SR; Infante JR
Invest New Drugs; 2018 Dec; 36(6):1016-1025. PubMed ID: 29611022
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Nogova L; Sequist LV; Perez Garcia JM; Andre F; Delord JP; Hidalgo M; Schellens JH; Cassier PA; Camidge DR; Schuler M; Vaishampayan U; Burris H; Tian GG; Campone M; Wainberg ZA; Lim WT; LoRusso P; Shapiro GI; Parker K; Chen X; Choudhury S; Ringeisen F; Graus-Porta D; Porter D; Isaacs R; Buettner R; Wolf J
J Clin Oncol; 2017 Jan; 35(2):157-165. PubMed ID: 27870574
[TBL] [Abstract][Full Text] [Related]
17. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Falchook GS; Kurzrock R; Amin HM; Xiong W; Fu S; Piha-Paul SA; Janku F; Eskandari G; Catenacci DV; Klevesath M; Bruns R; Stammberger U; Johne A; Bladt F; Friese-Hamim M; Girard P; El Bawab S; Hong DS
Clin Cancer Res; 2020 Mar; 26(6):1237-1246. PubMed ID: 31822497
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
20. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas.
Moreno V; Vieito M; Sepulveda JM; Galvao V; Hernández-Guerrero T; Doger B; Saavedra O; Carlo-Stella C; Michot JM; Italiano A; Magagnoli M; Carpio C; Pinto A; Sarmiento R; Amoroso B; Aronchik I; Filvaroff E; Hanna B; Wei X; Nikolova Z; Braña I
Nat Commun; 2023 Mar; 14(1):1359. PubMed ID: 36914652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]